Forsta AP Fonden Buys 1,700 Shares of Solventum Corporation $SOLV

Forsta AP Fonden lifted its position in Solventum Corporation (NYSE:SOLV) by 6.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,100 shares of the company’s stock after buying an additional 1,700 shares during the quarter. Forsta AP Fonden’s holdings in Solventum were worth $2,207,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of SOLV. Envestnet Asset Management Inc. increased its holdings in Solventum by 7.1% during the 1st quarter. Envestnet Asset Management Inc. now owns 193,510 shares of the company’s stock worth $14,714,000 after acquiring an additional 12,881 shares during the period. Massachusetts Financial Services Co. MA purchased a new position in shares of Solventum during the 1st quarter valued at $956,000. Victory Capital Management Inc. grew its position in shares of Solventum by 45.2% during the 1st quarter. Victory Capital Management Inc. now owns 98,264 shares of the company’s stock valued at $7,472,000 after purchasing an additional 30,610 shares in the last quarter. Jackson Creek Investment Advisors LLC bought a new position in shares of Solventum in the first quarter worth $283,000. Finally, Financial Harvest LLC purchased a new stake in shares of Solventum in the first quarter worth $6,976,000.

Analyst Upgrades and Downgrades

SOLV has been the subject of several recent analyst reports. Jefferies Financial Group began coverage on Solventum in a research report on Thursday, September 11th. They set a “hold” rating and a $80.00 target price for the company. Wells Fargo & Company lifted their price target on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research report on Monday, September 15th. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research report on Thursday, October 30th. Zacks Research raised shares of Solventum from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 15th. Finally, UBS Group lifted their target price on shares of Solventum from $77.00 to $79.00 and gave the company a “neutral” rating in a research report on Monday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Solventum currently has a consensus rating of “Hold” and a consensus price target of $85.56.

Solventum Price Performance

Shares of Solventum stock opened at $75.59 on Friday. The firm has a market capitalization of $13.11 billion, a PE ratio of 8.71, a price-to-earnings-growth ratio of 2.93 and a beta of 0.48. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.03. Solventum Corporation has a 12 month low of $60.70 and a 12 month high of $85.92. The business’s 50-day moving average price is $72.14 and its 200-day moving average price is $72.70.

Solventum (NYSE:SOLV) last issued its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.07. The business had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.05 billion. Solventum had a return on equity of 28.01% and a net margin of 18.13%.Solventum’s revenue for the quarter was up .7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.64 earnings per share. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Sell-side analysts forecast that Solventum Corporation will post 6.58 EPS for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.